384 related articles for article (PubMed ID: 22920047)
1. Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use.
Casciano JP; Singer DE; Kwong WJ; Fox ES; Martin BC
Am J Cardiovasc Drugs; 2012 Oct; 12(5):313-23. PubMed ID: 22920047
[TBL] [Abstract][Full Text] [Related]
2. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
Agarwal S; Bennett D; Smith DJ
Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
[TBL] [Abstract][Full Text] [Related]
3. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
Cullen MW; Kim S; Piccini JP; Ansell JE; Fonarow GC; Hylek EM; Singer DE; Mahaffey KW; Kowey PR; Thomas L; Go AS; Lopes RD; Chang P; Peterson ED; Gersh BJ;
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):461-9. PubMed ID: 23759473
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
[TBL] [Abstract][Full Text] [Related]
5. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?
Zimetbaum PJ; Thosani A; Yu HT; Xiong Y; Lin J; Kothawala P; Emons M
Am J Med; 2010 May; 123(5):446-53. PubMed ID: 20399322
[TBL] [Abstract][Full Text] [Related]
6. Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation.
Man-Son-Hing M; Laupacis A
Arch Intern Med; 2002 Mar; 162(5):541-50. PubMed ID: 11871922
[TBL] [Abstract][Full Text] [Related]
7. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.
Casciano JP; Dotiwala ZJ; Martin BC; Kwong WJ
J Manag Care Pharm; 2013 May; 19(4):302-16. PubMed ID: 23627576
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and predictors of warfarin use in patients with atrial fibrillation at low or intermediate risk and relation to thromboembolic events.
Chae SH; Froehlich J; Morady F; Oral H
Clin Cardiol; 2011 Oct; 34(10):640-4. PubMed ID: 21994084
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
[TBL] [Abstract][Full Text] [Related]
11. Prevention of stroke in patients with atrial fibrillation.
Olsson SB; Halperin JL
Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
[TBL] [Abstract][Full Text] [Related]
12. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
O'Brien CL; Gage BF
JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
[TBL] [Abstract][Full Text] [Related]
13. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
Albert NM
Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
[TBL] [Abstract][Full Text] [Related]
14. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation for stroke prevention in elderly patients with non-valvular atrial fibrillation: what are the obstacles?
Wong CW
Hong Kong Med J; 2016 Dec; 22(6):608-15. PubMed ID: 27920399
[TBL] [Abstract][Full Text] [Related]
16. Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis.
Desbiens NA
J Am Geriatr Soc; 2002 May; 50(5):863-9. PubMed ID: 12028173
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.
Janzic A; Kos M
Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096
[TBL] [Abstract][Full Text] [Related]
18. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation.
Eckman MH; Singer DE; Rosand J; Greenberg SM
Circ Cardiovasc Qual Outcomes; 2011 Jan; 4(1):14-21. PubMed ID: 21139092
[TBL] [Abstract][Full Text] [Related]
19. Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation.
Guo Y; Wang H; Tian Y; Wang Y; Lip GYH
Chest; 2015 Jul; 148(1):62-72. PubMed ID: 25501045
[TBL] [Abstract][Full Text] [Related]
20. Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis.
Chew DS; Zhou K; Pokorney SD; Matchar DB; Vemulapalli S; Allen LA; Jackson KP; Samad Z; Patel MR; Freeman JV; Piccini JP
Ann Intern Med; 2022 Sep; 175(9):1230-1239. PubMed ID: 35969865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
